Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05853900 · ClinicalTrials.gov registry record · NA

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

A NA study of Migraine and Headache, sponsored by Click Therapeutics.

Completed
Registry status
NA
Development phase
568
Enrollment target
1
Study location

NCT05853900: Completed NA study of Migraine and Headache, sponsored by Click Therapeutics.

NCT05853900 is a NA study of Migraine and Headache that has completed, run by Click Therapeutics. The registered enrollment target is 568 participants, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (61% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05853900, a NA study of Migraine and Headache, has completed, sponsored by Click Therapeutics.

COMPLETED
Registry status
NA
Development phase
568 participants
Enrollment target
1
Study location

Study Summary

Randomized study of two digital therapeutics for the prevention of episodic migraine

Primary Outcome

Change in the number of MMDs from baseline (28-day Run-in Period) to Week 12 (previous 28 days, Week 9 through Week 12).

Interventions

  • DEVICE ReMMi-D Digital Therapeutic

Study Locations (1)

New York

  • Click Therapeutics - New York

Trial Details

FieldValue
Enrollment Target 568 participants
Start Date 2023-03-28
Est. Completion 2024-05-07
Phase NA
Click Therapeutics

15 total trials

What the finished NCT05853900 record still lists

NCT05853900 is an interventional study that assigns participants to a tested intervention. The registered 568 participants enrollment target is mid-sized for trials with a published cap, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (61% higher).

The record links to 4 conditions, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which ReMMi-D Digital Therapeutic is the first listed.

NCT05853900 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05853900 about?

NCT05853900 is a clinical study titled "Study of Two Digital Therapeutics for the Prevention of Episodic Migraine". Randomized study of two digital therapeutics for the prevention of episodic migraine

What is the current status of trial NCT05853900?

This trial is currently completed. It is a NA study. The enrollment target is 568 participants. The study started on 2023-03-28. Estimated completion is 2024-05-07.

What conditions does trial NCT05853900 study?

This clinical trial studies the following conditions: Migraine, Headache, Episodic Migraine, Headache, Migraine.

What interventions are being tested in trial NCT05853900?

The interventions under investigation include: ReMMi-D Digital Therapeutic (DEVICE).

Who is sponsoring clinical trial NCT05853900?

This trial is sponsored by Click Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05853900 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05853900's enrollment target sits among peer trials

568 19th of 102 higher than 84 of 102 other Migraine trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05472441 · 568 participants · NA

    Linking Education, Produce Provision, and Community Referrals to Improve Diabetes Care (LINK)

  • NCT05000645 · 570 participants · NA

    Grocery Delivery and Healthy Weight Gain Among Low-income Pregnant Young Women

  • NCT06239844 · 570 participants · NA

    Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English

  • NCT06701903 · 570 participants · Phase 2

    Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05853900, the US trial registry maintained by the National Library of Medicine. NCT05853900 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.